NightstaRx Boasts Advantage Over Spark In Inherited Retinal Disease
This article was originally published in Scrip
Executive Summary
Spun out from the University of Oxford, new born NightstarRx is finding its feet in the biopharma field and has closed a $35m series B funding, with which it will boost its inherited retinal disease pipeline.